InflaRx (IFRX) has received a new Buy rating, initiated by H.C. Wainwright analyst, Matthew Keller.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Matthew Keller has given his Buy rating due to a combination of factors that highlight InflaRx’s potential in the market. The company has a promising strategy targeting the C5a/C5aR axis to combat inflammation, with its lead assets vilobelimab and INF904 showing significant promise. Vilobelimab, marketed as GOHIBIC, is already approved in the EU for specific COVID-19 patients and has received emergency use authorization in the U.S., indicating a strong validation of its approach.
Moreover, Keller believes that the commercial potential of GOHIBIC in the U.S. is underappreciated, and INF904’s Phase 1 data suggest it could be a best-in-class treatment. Despite a crowded market, there remains a high unmet need in conditions like CSU and HS, where INF904’s properties could offer broad applicability. Additionally, InflaRx’s solid financial position, with a strong cash balance, provides a runway into 2027, further supporting the stock’s undervaluation and potential for significant upside.